Bremazocine
From Wikipedia, the free encyclopedia
This is the current revision of this page, as edited by Maxim Masiutin (talk | contribs) at 10:44, 11 January 2024 (Added bibcode. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.). The present address (URL) is a permanent link to this version.
Revision as of 10:44, 11 January 2024 by Maxim Masiutin (talk | contribs) (Added bibcode. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.)
(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Group of stereoisomers
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H29NO2 |
Molar mass | 315.457 g·mol−1 |
3D model (JSmol) | |
|
Bremazocine is a κ-opioid receptor agonist related to pentazocine. It has potent and long-lasting analgesic and diuretic effects.[1] It has 200 times the activity of morphine, but appears to have no addictive properties and does not depress breathing.[2] The crystal structure of bremazocine was determined in 1984 [3]
See also[edit]
References[edit]
- ^ Dortch-Carnes J, Potter DE (2005). "Bremazocine: a kappa-opioid agonist with potent analgesic and other pharmacologic properties". CNS Drug Reviews. 11 (2): 195–212. doi:10.1111/j.1527-3458.2005.tb00270.x. PMC 6741727. PMID 16007240.
- ^ Patrick G (2013). An Introduction to Medicinal Chemistry (5th expanded ed.). Oxford University Press. p. 641. ISBN 978-0199697397.
- ^ Verlinde CL, Blaton NM, De Ranter CJ, Peeters OM (1984). "5-Ethyl-2'-hydroxy-2-[(1-hydroxycyclopropyl) methyl]-9, 9-dimethyl-6, 7-benzomorphan hydrochloride (bremazocine), C20H29NO2. HCl". Acta Crystallogr. C. 40 (10): 1759–1761. Bibcode:1984AcCrC..40.1759V. doi:10.1107/S0108270184009434.
Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Others |
|
μ-opioid (MOR) |
| ||||
---|---|---|---|---|---|
δ-opioid (DOR) |
| ||||
κ-opioid (KOR) |
| ||||
Nociceptin (NOP) |
| ||||
Others |
|